Brightgene Bio-medical Technology Co., Ltd.

This early-stage study tests an experimental daily pill, BGM0504, in 80 non-diabetic adults who are overweight or obese. The main goal is to check safety and how the body processes the drug, while also measuring weight changes over 11 weeks. Participants are randomly assigned to …

This study tests a new drug called BGM0504 against the existing weight-loss medication tirzepatide in adults with obesity. About 90 participants will take one of the two drugs for 26 weeks to see which leads to more weight loss and fewer side effects. The goal is to find a safe a…

This early-stage study tests a new drug called BGM1812 in 60 overweight or obese but otherwise healthy adults. The goal is to see if it is safe, how the body processes it, and whether it helps with weight loss. Participants receive either the drug or a placebo as an injection und…

This study tests a new medicine called BGM0504 against the well-known drug semaglutide (like Ozempic) in people with type 2 diabetes. All participants take metformin and then get either BGM0504 or semaglutide once a week. The goal is to see which works better at lowering blood su…

This early-stage study tests an experimental pill called BGM0504 in healthy and non-diabetic overweight or obese Chinese adults. The main goal is to check safety and how the body processes the drug. Researchers will also measure weight changes after 8 weeks. The study involves 75…

This early-stage study is testing an investigational drug called BGM1812 in healthy and non-diabetic overweight or obese Chinese adults. The main goal is to check the drug's safety and how the body processes it. Participants will receive either the drug or a placebo by injection,…

This study looks at how a high-fat meal and different ways of taking the drug BGM0504 affect its levels in the body. It involves 144 healthy Chinese adults aged 18 to 55. The goal is to understand the drug's behavior and safety, not to treat any disease.

This study checks if two experimental versions of BGM0504 injection are equivalent to the standard version in overweight or obese adults. About 144 participants aged 18-55 will receive a single dose. The main goal is to compare drug levels in the blood and monitor any side effect…